Brokerages Set Urogen Pharma (NASDAQ:URGN) PT at $32.86

Shares of Urogen Pharma (NASDAQ:URGN) have been given a consensus rating of “Buy” by the eight ratings firms that are currently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. The average 12-month price target among brokers that have updated their coverage on the stock in the last year is $32.86.

Several research analysts recently commented on URGN shares. Scotiabank reissued an “outperform” rating on shares of Urogen Pharma in a research note on Friday, June 13th. Guggenheim reissued a “buy” rating and issued a $30.00 price objective (up from $15.00) on shares of Urogen Pharma in a research note on Friday, June 13th. HC Wainwright raised Urogen Pharma from a “neutral” rating to a “buy” rating and set a $50.00 price objective for the company in a research note on Monday, June 16th. D. Boral Capital reissued a “buy” rating and issued a $25.00 price objective on shares of Urogen Pharma in a research note on Thursday, June 12th. Finally, The Goldman Sachs Group set a $16.00 price objective on Urogen Pharma and gave the company a “neutral” rating in a research note on Friday, June 13th.

Urogen Pharma Trading Down 4.4%

Shares of URGN stock opened at $13.11 on Tuesday. The company has a debt-to-equity ratio of 4.77, a current ratio of 5.65 and a quick ratio of 5.47. The company has a market cap of $604.50 million, a price-to-earnings ratio of -4.12 and a beta of 0.40. The stock has a 50 day simple moving average of $9.26 and a 200-day simple moving average of $10.17. Urogen Pharma has a 1-year low of $3.42 and a 1-year high of $18.15.

Urogen Pharma (NASDAQ:URGN) last announced its earnings results on Monday, May 12th. The company reported ($0.92) earnings per share for the quarter, missing the consensus estimate of ($0.83) by ($0.09). The business had revenue of $20.25 million for the quarter, compared to analyst estimates of $22.71 million. Urogen Pharma had a negative return on equity of 97,487.15% and a negative net margin of 150.68%. On average, equities research analysts expect that Urogen Pharma will post -3.12 EPS for the current fiscal year.

Insiders Place Their Bets

In other Urogen Pharma news, insider Mark Schoenberg sold 5,162 shares of the firm’s stock in a transaction on Monday, June 9th. The stock was sold at an average price of $7.37, for a total value of $38,043.94. Following the completion of the sale, the insider now directly owns 153,378 shares of the company’s stock, valued at $1,130,395.86. This trade represents a 3.26% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 5.10% of the company’s stock.

Institutional Trading of Urogen Pharma

Hedge funds and other institutional investors have recently modified their holdings of the stock. CWM LLC increased its stake in shares of Urogen Pharma by 6,047.1% in the 1st quarter. CWM LLC now owns 5,225 shares of the company’s stock worth $58,000 after acquiring an additional 5,140 shares during the last quarter. KLP Kapitalforvaltning AS purchased a new position in shares of Urogen Pharma during the 4th quarter worth $59,000. Lazard Asset Management LLC purchased a new position in shares of Urogen Pharma during the 4th quarter worth $67,000. GAMMA Investing LLC grew its holdings in shares of Urogen Pharma by 6,908.4% during the 1st quarter. GAMMA Investing LLC now owns 7,499 shares of the company’s stock worth $83,000 after purchasing an additional 7,392 shares during the period. Finally, Aquatic Capital Management LLC purchased a new position in shares of Urogen Pharma during the 4th quarter worth $101,000. 91.29% of the stock is owned by institutional investors and hedge funds.

Urogen Pharma Company Profile

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.